Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1912 - Discovery of novel 2beta-hydroxybetulinic acid 3beta-oliate via NF-_B pathway in Diethylnitrosamine induced Hepatocellular carcinoma in rats (20P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Danish Ahmed

Citation

Annals of Oncology (2017) 28 (suppl_10): x1-x6. 10.1093/annonc/mdx652

Authors

D. Ahmed1, M. Sharma2

Author affiliations

  • 1 Department Of Pharmaceutical Sciences, Sam Higginbottom Institute of Agriculture, Technology & Sciences (SHIATS), 211007 - Allahabad/IN
  • 2 Dept. Of Pharmacology, Jamia Hamdard, 110019 - New Delhi/IN
More

Resources

Abstract 1912

Background

Hepatocellular carcinoma (HCC) is the one of the major health problem in the world, is a leading cause of cancer related mortality. NF-kB pathways is considered as the singling pathway which activates the various cellular function including cell expansion, survival, proliferation and vesicular transport and found frequently dysregulated pathway in HCC. Consequently, natural product based inhibitors play a significant role in the NF-kB pathway and extensively scrutinized in the targeting the cancer in recent years. Present study was aimed to scrutinize the effect of 2beta-hydroxybetulinic acid 3beta-oliate (HBO) as NF-kB inhibitors for hepatic cancer.

Methods

Swiss albino Wistar rats (48) were divided into four groups. Diethylnitrosamine (DEN) (200 mg/kg) dose was used for induction the HCC in rats and treated with the HBO for 22 weeks. Pro-inflammatory cytokines including IL-6, TNF-α, IL-1β and NF-κB expression were estimated, respectively. Docking analysis was also performed with NF-kB (PDB:1NFK) to explicate imperative structural residues essential for bioactivity.

Results

HBO significantly (p 

Conclusions

Collectively, we may conclude that HBO has shown excellent activity towards down-regulation of HCC via inhibition of NF-kB pathways supported by molecular docking research analysis. Therefore, HBO could be a potential candidate for hepatic cellular carcinoma.

Clinical trial identification

Legal entity responsible for the study

SHUATS

Funding

SHUATS

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings